The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 29, 2007
Filed:
Jun. 01, 2004
Travis Mickle, Charlottesville, VA (US);
Suma Krishnan, Blacksburg, VA (US);
James Scott Moncrief, Blacksburg, VA (US);
Christopher Lauderback, Blacksburg, VA (US);
Barney Bishop, Annandale, VA (US);
Rob Oberlender, Blacksburg, VA (US);
Thomas Piccariello, Blacksburg, VA (US);
Travis Mickle, Charlottesville, VA (US);
Suma Krishnan, Blacksburg, VA (US);
James Scott Moncrief, Blacksburg, VA (US);
Christopher Lauderback, Blacksburg, VA (US);
Barney Bishop, Annandale, VA (US);
Rob Oberlender, Blacksburg, VA (US);
Thomas Piccariello, Blacksburg, VA (US);
New River Pharmaceuticals Inc., Radford, VA (US);
Abstract
The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.